Cargando…
The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a progressive disease that usually affects elderly people. It has a poor prognosis and there are limited therapies. Since epigenetic alterations are associated with IPF, histone deacetylase (HDAC) inhibitors offer a novel therapeutic strategy to address the unm...
Autores principales: | Conforti, Franco, Davies, Elizabeth R., Calderwood, Claire J., Thatcher, Thomas H., Jones, Mark G., Smart, David E., Mahajan, Sumeet, Alzetani, Aiman, Havelock, Tom, Maher, Toby M., Molyneaux, Philip L., Thorley, Andrew J., Tetley, Teresa D., Warner, Jane A., Packham, Graham, Ganesan, A., Skipp, Paul J., Marshall, Benjamin J., Richeldi, Luca, Sime, Patricia J., O'Reilly, Katherine M.A., Davies, Donna E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564721/ https://www.ncbi.nlm.nih.gov/pubmed/28467787 http://dx.doi.org/10.18632/oncotarget.17114 |
Ejemplares similares
-
Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin
por: Sager, Philip T, et al.
Publicado: (2015) -
Paracrine SPARC signaling dysregulates alveolar epithelial barrier integrity and function in lung fibrosis
por: Conforti, Franco, et al.
Publicado: (2020) -
Use of class I histone deacetylase inhibitor romidepsin in combination regimens
por: Petrich, Adam, et al.
Publicado: (2016) -
The Histone Deacetylase Inhibitor Romidepsin Spares Normal Tissues While Acting as an Effective Radiosensitizer in Bladder Tumors in Vivo
por: Paillas, Salome, et al.
Publicado: (2020) -
Chromobacterium spp. mediate their anti-Plasmodium activity through secretion of the histone deacetylase inhibitor romidepsin
por: Saraiva, Raúl G., et al.
Publicado: (2018)